In The News
-
Empirico Raises $17M, Inks 3-Year Antisense Collaboration with Ionis
Xconomy San Diego —Empirico, a biotech that has developed tools to analyze genomics data and use those insights to identify potential therapeutic targets, has signed a collaboration deal with antisense drug developer Ionis Pharmaceuticals that includes a $10 million equity investment.
-
Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline
BIOCENTURY—Ionis is turning to two young biotechs to build off the success of its antisense oligonucleotides and expand the reach of its platform. The company announced a pair of deals with Empirico and Aro on Thursday, designed to bring antisense therapeutics into new tissues and indications.